Tg Therapeutics is a biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of various hematologic malignancies and autoimmune diseases. With a strong emphasis on targeted therapies, the company aims to improve patient outcomes through its proprietary drug candidates, which are designed to engage the immune system in a more effective manner. Tg Therapeutics is committed to advancing its research and development efforts to address unmet medical needs in these challenging therapeutic areas, leveraging the latest scientific advancements to enhance patient care. Read More
Let's delve into the US markets on Monday and uncover the stocks that are experiencing notable gaps in today's session. Below, you'll find the gap up and gap down stocks.
TG THERAPEUTICS INC (NASDAQ:TGTX) shows strong earnings momentum and a bullish technical setup, making it a candidate for high-growth investors. The stock has solid revenue growth, improving margins, and a favorable chart pattern.
TG Therapeutics (TGTX) meets Minervini's Trend Template with strong technicals and high-growth fundamentals, including 1,300% EPS growth and 90% revenue expansion. A breakout above $37.27 could signal further upside.
Jim Cramer recommends buying Rio Tinto due to its high yield. TG Therapeutics is also a buy, with strong first-quarter sales and potential for market share growth.
TG Therapeutics (TGTX) shows strong earnings momentum with 142% EPS growth and a bullish technical setup, making it a candidate for high-growth investors.
The company, however, raised its full-year 2025 global net revenue target to approximately $575 million, up from its previous guidance of $540 million.
Uncover the potential of TG THERAPEUTICS INC, a growth stock reasonably priced. NASDAQ:TGTX is excelling in growth aspects, maintaining a healthy financial position, and still offers an attractive valuation.
